Evidence map›Paper›PMID 35566110›Full record

ReviewMolecules (Basel, Switzerland)2022

Silk Fibroin-Based Biomaterials for Tissue Engineering Applications.

Guangfei Li, Shan Sun

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
8.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 116 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Application of Transgenic Silk Fibroin to Biomaterials.Biotechnology and bioengineering · 2026
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Clinical progress and prospects of biodegradable intestinal stents.American journal of translational research · 2026
    Review
  12. Review
  13. Article
  14. Article
  15. Recent Advances in Silk Fibroin Derived fromJournal of functional biomaterials · 2025
    Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Guangfei LiENT Institute and Otorhinolaryngology Department of Eye & ENT Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Fudan University, Shanghai 200031, China.
Shan SunENT Institute and Otorhinolaryngology Department of Eye & ENT Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Fudan University, Shanghai 200031, China.ORCID 0000-0003-2142-4307
Eye & ENT Hospital of Fudan University · CN

Funding

National Natural Science Foundation of China 81970879
6 · The paper itself

Abstract

Tissue engineering (TE) involves the combination of cells with scaffolding materials and appropriate growth factors in order to regenerate or replace damaged and degenerated tissues and organs. The scaffold materials serve as templates for tissue formation and play a vital role in TE. Among scaffold materials, silk fibroin (SF), a naturally occurring protein, has attracted great attention in TE applications due to its excellent mechanical properties, biodegradability, biocompatibility, and bio-absorbability. SF is usually dissolved in an aqueous solution and can be easily reconstituted into different forms, including films, mats, hydrogels, and sponges, through various fabrication techniques, including spin coating, electrospinning, freeze drying, and supercritical CO

Indexed as

FibroinsBiocompatible MaterialsHydrogelsPorositySilkTissue EngineeringTissue ScaffoldsBiocompatible MaterialsFibroinsHydrogelsSilkbiomaterialsilk fibrointissue engineering

Identifiers

PMID35566110
PMCPMC9103528
OpenAlexW4224921418

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.